Cellular Biomedicine Group Announces Appointment of New Member to the Board of Directors
July 12 2016 - 8:30AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biomedicine firm engaged in the
development of effective stem cell therapies for degenerative
diseases and immunotherapies for cancer, today announced the
appointment of Dr. Zhou Hansheng as a Director of the Company,
effective immediately.
“Dr. Zhou is a well-respected and seasoned
healthcare and technology executive with over twenty-eight years of
experience in developing new technologies within China,” said Terry
A. Belmont, Chairman of the Board of CBMG. “We are delighted to
welcome him to the Board and look forward to his invaluable
perspective and contributions towards establishing strategic
partnerships and realizing the commercialization of the Company’s
dual technology platforms.”
Dr. Zhou commented, “I am honored to join the
seasoned team at CBMG who seeks to turn translational medicine into
clinical benefits serving a large patient population, and look
forward to being a part of this important stage of the Company’s
growth and success.”
About Dr. Zhou HanshengDr. Zhou
currently serves as Chief Executive Officer of Wuhan Dangdai
Science & Technology Industries (Group) Co., Ltd, a China-based
privately held conglomerate with a substantial medical and
pharmaceutical portfolio in China, including the Hong Kong
subsidiary Dangdai International Group Co., Limited, which is a
major shareholder of CBMG. He previously served as the CFO and
Managing Director of Wuhan Humanwell Healthcare Group Co., Ltd.
With a bachelor’s degree in cell biology and a master’s degree in
animal physiology, Dr. Zhou earned his Ph.D. in applied chemistry
from the Beijing Institute of Technology.
About Cellular Biomedicine
GroupCellular Biomedicine Group, Inc. develops proprietary
cell therapies for the treatment of certain degenerative and
cancerous diseases. Our developmental stem cell and Immuno-Oncology
projects are the result of research and development by scientists
and doctors from China and the United States. Our
GMP facilities in China, consisting of nine independent cell
production lines, are designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking
StatementsStatements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024